Population pharmacokinetics and pharmacodynamics: An underutilized resource

Drug Information Journal

Volumn 32, Issue 3, 1998, Pages 693-710

  Tett, Susan E ^a   Holford, Nicholas H G ^b   McLachlan, Andrew J ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b NONE

Author keywords

Pediatric drug use; Pharmacodynamics; Pharmacostatistics; Population pharmacokinetics; Rational drug dosing

Indexed keywords

CAFFEINE; FLUCONAZOLE; RIVASTIGMINE; TACRINE;

AUSTRALIA; DRUG LEGISLATION; DRUG RESEARCH; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 0031826088     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159803200310     Document Type: Review

References (59)

1. Aarons L. Population pharmacokinetics: Theory and practice. Br J Clin Pharmacol. 1991;32:669-670.
2. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics: Theory and clinical application. Clin Pharmacokinet. 1985;11:387-401.
3. Sheiner LB, Grasela TH. An introduction to mixed effect modelling: concepts, definitions and justification. J Pharmacokinet Biopharm. 1991;Suppl 11S-23S.
4. Holford NHG, Peck CC. Population pharmacodynamic and drug development. In: van Boxtel CJ, Holford NHG, Danhof M, Eds. The in vivo study of drug action. London: Elsevier Science; 1992.
5. Vozeh S. Steimer J-L, Rowland M, Morselli P, Mentré F, Balant LP, Aarons L. The use of population pharmacokinetics in drug development. Clin Pharmacokinet. 1996;30:81-93.
6. Steimer J-L, Ebelin M-E, Van Bree J. Pharmacokinetic and pharmacodynamic data and models in clinical trials. Eur J Drug Metab Pharmacokinet, 1993;18:61-76.
7. Aarons L. Sparse data analysis. Eur J Drug Metab Pharmacokinet. 1993;18:97-100.
8. Kearns GL. Drug development for infants and children: Rescuing the therapeutic orphan. Drug Info J. 1996;30:1121-1123.
9. Shirkey H. Editorial comment: Therapeutic orphans. J Pediatr. 1968;72:119-120.
10. Cote CJ, Kauffman RE, Troendle GJ, Lambert GH. Is the "therapeutic orphan" about to be adopted? Pediatr. 1996;98:118-123.
11. Australian Drug Evaluation Committee. Report of the working party on the registration of drugs for use in children, October 1997.
12. Kauffman RE, Kearns GL. Pharmacokinetics studies in pediatric patients: Clinical and ethical considerations. Clin Pharmacokinet. 1992;23:10-29.
13. Reed MD. The ontogeny of drug disposition: Focus on drug absorption, distribution, and excretion. Drug Info J. 1996;30:1129-1134.
14. Leeder JS. Developmental aspects of drug metabolism in children. Drug Info J. 1996;30:1135-1143.
15. Roberts R, Maldonado S. FDA center for drug evaluation and research (CDER) pediatric plan and new regulations. Drug Info J. 1996;30:1125-1127.
16. FDA Center for Drug Evaluation and Research. Guidance for industry: Population pharmacokinetics. Draft Guidance, September 1997.
17. Wilson JT, Kearns GL, Murphy D, Yaffe SJ. Pediatric labelling requirements: Implications for pharmacokinetic studies. Clin Pharmacokinet. 1994;26:308-325.
18. Wade JR. Population pharmacokinetics and pharmacodynamics: European regulatory experiences. In: Balant LP, Aarons L, Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;48-53.
19. Ette El, Miller R, Gillespie WR, et al. The population approach: FDA experience. In: Aarons L, et al, Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;271-275.
20. CPMP/ICH/378/95 Dose-response information to support drug registration.
21. CPMP/ICH/379/95 Studies in support of special population: Geriatrics.
22. CPMP/EWP/560/95 Note for guidance on the Investigation of Drug Interactions.
23. Ludden TM. Evaluation of potential drug-drug interactions using the population approach. In: Aarons L, et al., Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;39-46.
24. CPMP/EWP/462/95 Note for Guidance on Clinical Investigation of Medicinal Products in Children.
25. CPMP/ICH/289/95 (Step 3) Note for guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data.
26. Aarons L, Balant LP, Mentré F, Morselli P, Rowland M, Steimer JL, Vozeh S. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol 1996;49:251-254.
27. Grasela TH, Donn SM. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. Dev Pharmacol Ther. 1985;8:374-383.
28. Tanigawara Y. Recent applications of population pharmacokinetic approach: Pre-marketing and postmarketing. Aarons L et al, Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;25-28.
29. Aarons L, Balant LP, Mentré F, Morselli P, Rowland M, Steimer JL, Vozeh S. Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software. Eur J Clin Pharmacol. 1994;46:389-391.
30. Collart L, Balschke TF, Boucher F, Prober CG. Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. Dev Pharmacol Ther. 1992;18:71-80.
31. Hale MD, Gillespie WR, Gupta SK, Holford NHG. Clinical trial simulation: Streamlining your drug development process. Appl Clin Trials. 1996;5:35-40.
32. del Mar Fernandez de Gatta M, Garcia MJ, Lanao JM, Dominguez-Gil A. Bayesian forecasting in paediatric populations. Clin Pharmacokinet. 1996;31: 325-330.
33. Lee TC, Charles BG, Steer P, Flenady V, Shearman A. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther. 1997;61:628-640.
34. McLachlan AJ, Tett SE. Pharmacokinetics of fluconazole in people with HIV infection; A population analysis. Br J Clin Pharmacol. 1996;41:291-298.
35. Tett S, Moore S, Ray J. Pharmacokinetics and bio-availability of fluconazole in two groups of males with HIV infection compared with a group of males without HTV infection. Antimicrob Agents Chemother. 1995;39:1835-1841.
36. Holford NHG, Peace K. The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol. 1994;47:17-24.
37. Holford NHG, Peace K. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA. 1992;89:11471-11475.
38. Holford NHG. Population models for Alzheimer's and Parkinson's disease. In: Aarons L, et al, Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;93-104.
39. Thomson AH, Way S, Bryson SM, McGovern EM, Kelman AW, Whiting B. Population pharmacokinetics of gentamicin in neonates. Dev Pharmacol Ther. 1998;11:173-179.
40. Delgado Iribarnegaray MF, Santo Bueldga D, Garcia Sanchez MJ, Otero MJ, Falcao AC, Dominguez-Gil A. Carbamazepine population pharmacokinetics in children: Mixed-effect models. Ther Drug Monit. 1997;19:132-139.
41. Thomson AH, Kerr S, Wright S. Population pharmacokinetics of caffeine in neonates and young infants. Ther Drug Monit. 1996;18:245-253.
42. Wiest DB, Pinson JB, Gal PS, Brundage RC, Schall S, Ransom JL, Weaver RL, Purohit D, Brown Y. Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus. Clin Pharmacol Ther. 1991;49:550-557.
43. Burtin P, Jacqz-Aigrain E, Girard P, Lenclen R, Magny JF, Betremieux P, Tehiry C, Desplanques L, Mussat P. Clin Pharmacol Ther. 1994;56:615-625.
44. Thomson AH, Tucker GT. Gerontokinetics - a reappraisal. Br J Clin Pharmacol, 1992;33:1-2.
45. Thomson AH, Kelly JG, Whiting B. Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension. Br J Clin Pharmacol. 1989;27:57-65.
46. Thomson AH, Rosario M, Murray LS, Elliot HL. Marimastat in healthy volunteers and patients with cancer. In: Aarons L, et al, Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;287.
47. Theis JGW, Koren G. Maternal and fetal clinical pharmacology. In Speight TM, Holford NHG, Eds. Avery's Drug Treatment. 4th Edition. Auckland: ADIS International; 1997;76-126.
48. Vanhove GF, Gries JM, Verotta D, Sheiner LB, Coombs R, Collier AC, Blaschke TF. Exposureresponse relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997;41:2433-2438.
49. Tucker GT, Rostami-Hodjegan A. Metabolic variability in populations. In Aarons L, et al, Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;9-13.
50. Rolan P. The contribution of clinical pharmacology surrogates and models to drug development - a critical appraisal. Br J Clin Pharmacol. 1997;44:219-225.
51. Holford NHG. The target concentration approach to clinical drug development. Clin Pharmacokinet. 1995;29:287-291.
52. Reigner BG, Williams PEO, Patel IH, Steimer JL, Peck C, van Brummelen P. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Clin Pharmacokinet. 1997;33:142-152.
53. Mentré F, Ebelin ME. Validation of population pharmacokinetic/pharmacodynamic analyses; Review of proposed approaches. In Aarons L, et al, Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;147-160.
54. Wang J, Endrenyi L. A computationally efficient approach for the design of population pharmacokinetic studies. J Pharmacokinet Biopharm. 1992;20:279-294.
55. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
56. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486-495.
57. Ette E, Ludden TM. Population pharmacokinetic modelling: The importance of informative graphics. Pharm Res. 1995;12:1845-1855.
58. Kearns GL, Weber W, Harnisch L, Darville T, Blumer JL, Powell K, Wells TG, Jacobs RF. Single dose pharmacokinetics of cefpirome in paediatric patients. Clin Drug Invest. 1995;10:71-85.
59. Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical and covariate models in population pharmacokinetic analysis. J Pharmacokinet Biopharm. 1994;22:165-177.